台灣泌尿科醫學會E-School

台灣泌尿科醫學會E-School

MP05-08: Anti-cancer effects and tumor marker role of glutathione s-transferase mu 5 in human bladder cancer_蔡長佑

2022-02-15 • 觀看: 2 • 回應: 0 • ppt
(WS3-1) Evidences and skills for disposable circumcision suture device_陳偉傑

2022-02-14 • 觀看: 37 • 回應: 0 • 連結
PD08-6: Immune checkpoint biomarker on circulating tumor cells as a potential predictor of therapeutic efficacy in urothelial carcinoma patients_賴姿君

2022-02-14 • 觀看: 17 • 回應: 0 • ppt
PD08-5: miR-375 suppresses upper tract urothelial carcinoma cell migration and invasion via targeting Derlin-1_詹鎮豪

2022-02-14 • 觀看: 6 • 回應: 0 • ppt
PD08-4: Partial cystectomy after neoadjuvant chemotherapy for muscle invasive bladder cancer_楊啟瑞

2022-02-14 • 觀看: 8 • 回應: 0 • ppt
PD08-3: Long non-coding RNA mediates cisplatin and gemcitabine resistance in upper tract urothelial carcinoma cells by sponging of miR-31_徐偉齊

2022-02-14 • 觀看: 7 • 回應: 0 • ppt
PD08-2: Treatment outcome and FGFR alteration rate in unresectable locally advanced or metastatic urothelial cancer in Taiwan_李建儀

2022-02-14 • 觀看: 10 • 回應: 0 • ppt
PD08-1: Can ERBT take place of the importance of traditional TURBt?_倪雪雰

2022-02-14 • 觀看: 7 • 回應: 0 • ppt
PD07-6: Experience with modified Makuuchi incision in the surgical treatment for huge retroperitoneal tumor_施孟宏

2022-02-14 • 觀看: 11 • 回應: 0 • ppt
PD07-5: Retrospective analysis of Hepatocellular carcinoma with adrenal metastasis treatment and prognosis – VGTCH experience_邱俊凱

2022-02-14 • 觀看: 7 • 回應: 0 • ppt
PD07-4: Hsa-mir-34a, as a novel autophagy regulator, inhibits STX-17-mediated fusion of autophagosomes with lysosomes_何肇晏

2022-02-14 • 觀看: 5 • 回應: 0 • ppt
PD07-3: Tumor characteristics and survival outcomes of renal cell carcinoma during the past decade in Taiwanese population: A dual-center retrospective study_張顥瀚

2022-02-14 • 觀看: 6 • 回應: 0 • ppt

Prev
491
492
493
494
495
496
497
498
499
500
Next
/ 1134